Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 Jun;186(3):388-401.
doi: 10.1007/s00213-005-0185-2. Epub 2005 Dec 15.

Action by and sensitivity to neuroactive steroids in menstrual cycle related CNS disorders

Affiliations
Review

Action by and sensitivity to neuroactive steroids in menstrual cycle related CNS disorders

Anna-Carin N-Wihlbäck et al. Psychopharmacology (Berl). 2006 Jun.

Abstract

Neuroactive steroids are a large group of substances having effect in the brain and on brain function. The steroids most studied are allopregnanolone (ALLO), tetrahydrodesoxycorticosterone (THDOC), pregnenolone sulfate (PS) dihydroepiandrosteronesulfate (DHEAS), and estradiol (E2). ALLO and THDOC are called gamma-aminobutyric acid (GABA) steroids as they are positive modulators of the GABAA receptor in a similar way as benzodiazepines, barbiturates, and alcohol. GABA steroids not only have similar behavioral effects as benzodiazepines and barbiturates but, possibly, also similar adverse effects as well. This review aims to elucidate the possible role that neuroactive steroids play in the development of mood disorders in women. One of the most clear-cut examples of the interaction between mood, neuroactive steroids, and the GABA system is premenstrual dysphoric disorder (PMDD), which is a cluster of negative mood symptoms occurring during the luteal phase of the menstrual cycle in 2-6% of reproductive women. Furthermore, certain women also experience adverse mood effects during sequential progestin addition to postmenopausal estrogen treatment, which is why the role of neuroactive steroids in postmenopausal women is also addressed in this review.

PubMed Disclaimer

References

    1. Brain Res. 2001 Aug 10;910(1-2):55-66 - PubMed
    1. Cell Mol Neurobiol. 1996 Apr;16(2):199-212 - PubMed
    1. J Clin Psychopharmacol. 1999 Oct;19(5):450-8 - PubMed
    1. Eur J Clin Pharmacol. 1999 Apr;55(2):125-30 - PubMed
    1. Neuroendocrinology. 1998 Feb;67(2):126-38 - PubMed

Publication types

MeSH terms

LinkOut - more resources